Brian J. Grindel

4 weeks ago | digitalcommons.library.tmc.edu | Brian J. Grindel |Brian Engel |Justin Ong |Anupallavi Srinivasamani

AbstractTherapeutic monoclonal antibodies directed against PD-L1 (e.g., atezolizumab) disrupt PD-L1:PD-1 signaling and reactivate exhausted cytotoxic T-cells in the tumor compartment. Although anti-PD-L1 antibodies are successful as immune checkpoint inhibitor (ICI) therapeutics, there is still a pressing need to develop high-affinity, low-molecular-weight ligands for molecular imaging and diagnostic applications.